With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...

Thursday, August 14, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Merck & Co.

Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set ...

Pfizer (PFE) stock is in focus as the company and Astellas (ALPMF) post a late-stage trial win for their cancer drug Padcev ...

IO Biotech (IOBT) stock rallies as cancer vaccine, Cylembio, with Merck's (MRK) Keytruda outperforms in a late-stage trial ...

Merck (MRK) recently announced positive topline results from its Phase 3 KEYNOTE-905 trial, showcasing efficacy for KEYTRUDA in patients with muscle-invasive bladder cancer, which adds substantial ...

Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...

Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and ...

Merck in 2019 inked a deal to evaluate the combination of its blockbuster cancer drug Keytruda with Pacdev from Astellas and Seagen, which Pfizer acquired in a $43 billion deal that closed in late ...

Pfizer’s Padcev plus Keytruda combo shows significant survival gains in muscle‑invasive bladder cancer and could become ...